Flag of the European Union EU Clinical Trials Register Help

Clinical trials for incyte

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    131 result(s) found for: incyte. Displaying page 3 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2018-004076-35 Sponsor Protocol Number: INCB01158-206 Start Date*: 2019-08-19
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized Open-Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma
    Medical condition: Relapsed or Refractory Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2018-004768-69 Sponsor Protocol Number: INCB54828-207 Start Date*: 2019-10-16
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectabl...
    Medical condition: Male and female participants at least 18 years of age who have a solid tumor malignancy with an activating FGFR mutation or fusion/rearrangement who have progressed on prior therapies and have no a...
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10065147 Malignant solid tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) DE (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-001981-13 Sponsor Protocol Number: INCB54707204 Start Date*: 2021-03-02
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of INCB054707 in Participants With Hidradenitis Suppurativa
    Medical condition: Hidradenitis Suppurativa
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004858 10020041 Hidradenitis suppurativa LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2019-004171-39 Sponsor Protocol Number: INCB39110-214 Start Date*: 2020-01-10
    Sponsor Name:Incyte Corporation
    Full Title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Participants With Bronchiolitis Obliterans Syndrome Following Lung Transplantation
    Medical condition: Bronchiolitis Obliterans Syndrome following Lung Transplantation
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10049202 Bronchiolitis obliterans LLT
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10029888 Obliterative bronchiolitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002286-17 Sponsor Protocol Number: INCB00928-201 Start Date*: 2022-04-19
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of INCB000928 in Participants With Fibrodysplasia Ossificans Progressiva
    Medical condition: Fibrodysplasia ossificans progressiva
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10068715 Fibrodysplasia ossificans progressiva PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) DE (Trial now transitioned) NL (Trial now transitioned) PT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-002205-19 Sponsor Protocol Number: INCB50465-202 Start Date*: 2017-07-26
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Multicenter, International, Open-Label, Safety and Efficacy Study of INCB050465 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Medical condition: Diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) PL (Completed) FR (Completed) ES (Temporarily Halted) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003123-42 Sponsor Protocol Number: INCB39110-213 Start Date*: 2021-03-17
    Sponsor Name:Incyte Corporation
    Full Title: A 2-Part, Phase 2, Open-Label Study of the Safety, Tolerability, and Efficacy of Itacitinib Immediate Release in Participants With Primary Myelofibrosis or Secondary Myelofibrosis (Post–Polycythemi...
    Medical condition: Primary Myelofibrosis or Secondary Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Prematurely Ended) FR (Completed) DE (Completed) ES (Prematurely Ended) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003415-98 Sponsor Protocol Number: INCB50465-304 Start Date*: 2021-01-21
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind, Placebo-Controlled Study of the PI3Kδ Inhibitor Parsaclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
    Medical condition: myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) FR (Completed) BE (Prematurely Ended) DE (Completed) NO (Completed) FI (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003130-21 Sponsor Protocol Number: INCB50465-313 Start Date*: 2021-03-10
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Combination of PI3Kδ Inhibitor Parsaclisib and Ruxolitinib in Participants With Myelofibrosis
    Medical condition: myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed) NO (Completed) FR (Completed) DK (Completed) FI (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002253-30 Sponsor Protocol Number: INCB39110-120 Start Date*: 2019-07-01
    Sponsor Name:Incyte Corporation
    Full Title: An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Itacitinib in Combination With Corticosteroids for the Treatment of Steroid-Naive Acute Graft-Versus-Host Disease in...
    Medical condition: Male or female, 28 days to less than 18 years of age, who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHD
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021428 - Immune system disorders 10066260 Acute graft versus host disease PT
    20.1 10021428 - Immune system disorders 10066262 Acute graft versus host disease in skin PT
    20.1 10021428 - Immune system disorders 10066264 Acute graft versus host disease in intestine PT
    20.1 10021428 - Immune system disorders 10066263 Acute graft versus host disease in liver PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) FR (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001321-14 Sponsor Protocol Number: INCB54828-201 Start Date*: 2017-01-12
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FG...
    Medical condition: Subjects with metastatic or surgically unresectable urothelial cancer (may include primary site from ureters, upper tract, renal pelvis, and bladder) with an FGF/FGFR alteration, who failed at leas...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10005003 Bladder cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) FR (Completed) ES (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2015-004991-31 Sponsor Protocol Number: INCB24360-301/MK3475-252/Keynote252 Start Date*: 2016-05-03
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Pembrolizumab (MK-3475) in Combination With Epacadostat or Placebo in Subjects with Unresectable or Metastatic Melanoma (Keynote-252 ...
    Medical condition: Melanoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10053571 Melanoma LLT
    20.0 100000004864 10027481 Metastatic melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) DK (Completed) IE (Completed) ES (Completed) PL (Completed) FR (Completed) BE (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000293-20 Sponsor Protocol Number: INCB18424-362 Start Date*: 2014-07-31
    Sponsor Name:Incyte Corporation
    Full Title: INCB 18424-362 A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor, Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of ...
    Medical condition: Male or female, 18 years or older with histologically or cytologically confirmed adenocarcinoma of the pancreas that is inoperable or metastatic.
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10033606 Pancreatic cancer non-resectable LLT
    17.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) ES (Completed) BE (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003305-18 Sponsor Protocol Number: INCB24360-310 Start Date*: 2018-03-23
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Global, Phase 3 Trial of Nivolumab Plus Epacadostat in Combination with Chemotherapy (platinum + 5-fluorouracil) versus the EXTREME Regimen (cetuximab + platinum + 5-fluorouracil) in ...
    Medical condition: Squamous Cell Carcinoma of the Head and Neck (SCCHN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-003304-43 Sponsor Protocol Number: INCB24360-309 Start Date*: 2018-04-12
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3, Randomized, Global Trial of Nivolumab and Epacadostat with Platinum Doublet Chemotherapy versus Platinum Doublet Chemotherapy in First-line Treatment of Stage IV or Recurrent Non-Small C...
    Medical condition: Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029515 Non-small cell lung cancer recurrent PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029522 Non-small cell lung cancer stage IV PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-000294-39 Sponsor Protocol Number: INCB18424-363 Start Date*: 2014-07-16
    Sponsor Name:Incyte Corporation
    Full Title: A Randomized, Double-Blind, Phase 3 Study of the JAK1/2 Inhibitor Ruxolitinib or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who ...
    Medical condition: Advanced or metastatic adenocarcinoma of the pancreas in patients that have failed or are intolerant to first-line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10033607 Pancreatic cancer recurrent LLT
    17.1 100000004864 10033606 Pancreatic cancer non-resectable LLT
    17.1 100000004864 10033605 Pancreatic cancer metastatic LLT
    17.1 100000004864 10033604 Pancreatic cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) AT (Prematurely Ended) DK (Completed) PT (Prematurely Ended) NL (Prematurely Ended) FR (Prematurely Ended) IE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002941-12 Sponsor Protocol Number: INCMGA0012-203 Start Date*: 2019-06-19
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2 Study of INCMGA00012 (PD-1 Inhibitor) in Participants With Selected Solid Tumors (POD1UM-203)
    Medical condition: Male or female, 18 years or older with histologically or cytologically confirmed diagnosis of : a. NSCLC with high PD-L1 expression (TPS ≥ 50%) and no EGFR, ALK, or ROS activating genomic tumor ab...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10080083 Advanced lung cancer LLT
    20.0 100000004864 10027481 Metastatic melanoma LLT
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    21.0 100000004864 10038395 Renal carcinoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) PL (Completed) ES (Ongoing) IT (Completed) RO (Ongoing)
    Trial results: View results
    EudraCT Number: 2017-003148-19 Sponsor Protocol Number: INCB50465-205 Start Date*: 2018-05-15
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 2, Open-Label, 2-Cohort, Multicenter Study of INCB050465, a PI3Kδ Inhibitor, in Relapsed or Refractory Mantle Cell Lymphoma Previously Treated With or Without a BTK Inhibitor.
    Medical condition: Mantle Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061275 Mantle cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) BE (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-000826-24 Sponsor Protocol Number: INCMGA0012-303 Start Date*: 2020-10-29
    Sponsor Name:Incyte Corporation
    Full Title: A Phase 3 Global, Multicenter, Double-Blind Randomized Study of Carboplatin-Paclitaxel With INCMGA00012 or Placebo in Participants With Inoperable Locally Recurrent or Metastatic Squamous Cell Carc...
    Medical condition: Male and female participants at least 18 years of age who have inoperable locally recurrent or metastatic Squamous Carcinoma of the Anal Canal (SCAC) not previously treated with systemic chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10002127 Anal canal cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) GB (GB - no longer in EU/EEA) NO (Trial now transitioned) DE (Trial now transitioned) FR (Trial now transitioned) DK (Trial now transitioned) IT (Trial now transitioned) SE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-002244-23 Sponsor Protocol Number: INCB24360-901 Start Date*: 2021-07-28
    Sponsor Name:Incyte Corporation
    Full Title: An Open-Label, Randomized, Phase 2, Umbrella Study of Various Neoadjuvant Therapies for Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse ...
    Medical condition: Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Cisplatin-Ineligible or Refuse Cisplatin Therapy and Undergoing Radical Cystectomy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10064467 Urothelial carcinoma LLT
    20.0 100000004864 10046714 Urothelial carcinoma bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri Jun 20 07:37:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA